-Demonstrates progress executing strategy to advance at least three
new medicines addressing significant unmet needs into later-stage
development by 2017/2018-
CAMBRIDGE, Mass.--(BUSINESS WIRE)--
Ironwood
Pharmaceuticals, Inc. (NASDAQ: IRWD) today announced that it
initiated a Phase IIb clinical trial of IW-3718 in patients with
refractory gastroesophageal reflux disease (GERD). Refractory GERD is a
chronic condition in which patients continue to suffer from symptoms
such as heartburn and regurgitation despite receiving treatment with a
proton pump inhibitor (PPI). Data from this trial are expected in 2017.
"There is a significant unmet medical need among the estimated 10
million patients in the U.S. with refractory GERD," said Mark Currie,
Ph.D., chief scientific officer and president of research and
development at Ironwood. "For these patients, PPIs are not enough to
control their heartburn and regurgitation. They continue to suffer from
frequent and bothersome symptoms, and there is a dearth of approved
prescription medicines for this condition. For these reasons, the
advancement of IW-3718 is a top priority for Ironwood."
The randomized, double-blind, placebo-controlled, dose-ranging Phase IIb
clinical trial is designed to evaluate the safety, efficacy, and
dose-response relationship of IW-3718. The trial is expected to enroll
approximately 260 adult patients who have been diagnosed with GERD and
report experiencing heartburn or regurgitation at least four days per
week during the previous eight weeks despite ongoing PPI treatment. The
study design calls for eligible patients to continue taking their daily
PPI therapy and to be randomized to receive additional treatment with
placebo or one of three doses of IW-3718, twice-daily for eight weeks.
The primary efficacy endpoint is change from baseline in heartburn
severity.
Ironwood previously reported positive data from its randomized,
double-blind, placebo-controlled Phase IIa study of IW-3718 for
refractory GERD. Data from that study showed that IW-3718 improved
heartburn severity in the intent-to-treat population. IW-3718 was
generally well-tolerated with the most common adverse event being
constipation.
About Refractory Gastroesophageal Reflux Disease
An
estimated 45 million Americans have gastroesophageal reflux disease
(GERD), an estimated 10 million of whom are thought to suffer from the
refractory form of the condition, meaning they continue to experience
symptoms such as heartburn and regurgitation despite receiving the
current standard of care treatment with a proton pump inhibitor (PPI).
While PPIs suppress production of stomach acid, research suggests reflux
of bile from the intestine into the stomach and esophagus may play a
role in the ongoing symptoms of refractory GERD. There are few
FDA-approved treatment options for these patients. If left untreated,
refractory GERD can lead to serious complications including Barrett's
esophagus and, in rare instances, esophageal cancer.
About IW-3718
IW-3718 is a novel, investigational gastric
retentive formulation of a bile acid sequestrant, developed by Ironwood
using the proprietary Acuform® drug delivery technology licensed from
Depomed, Inc. IW-3718 is designed to remain in the stomach and duodenum
(upper small intestine) over an extended period of time and to work in
combination with a PPI to reduce the detrimental effects of bile and
acid on the esophagus.
About Ironwood Pharmaceuticals
Ironwood
Pharmaceuticals (NASDAQ: IRWD) is a commercial biotechnology company
focused on creating medicines that make a difference for patients,
building value for our fellow shareholders, and empowering our
passionate team. We are advancing an innovative pipeline of medicines in
multiple areas of significant unmet need, including irritable bowel
syndrome with constipation (IBS-C)/chronic idiopathic constipation
(CIC), vascular and fibrotic diseases, and refractory gastroesophageal
reflux disease, among others. We discovered, developed and are
commercializing linaclotide, the U.S. branded prescription market leader
in the IBS-C/CIC category, and we are applying our proven R&D and
commercial capabilities to advance multiple internally-developed and
externally-accessed product opportunities. Ironwood was founded in 1998
and is headquartered in Cambridge, Mass. For more information, please
visit www.ironwoodpharma.com
or www.twitter.com/ironwoodpharma;
information that may be important to investors will be routinely posted
in both these locations.
Any trademarks referred to in this press release are the property of
their respective owners. All rights reserved.
This press release contains forward-looking statements. Investors are
cautioned not to place undue reliance on these forward-looking
statements, including, but not limited to, statements about the clinical
program for IW-3718, including the design, size and scope of the Phase
IIb study and the completion thereof, the size of the potential patient
population, the data to be generated from the Phase IIb study, the
timing that these data are expected to be available, and the cause of
the symptoms suffered by the potential patient population. Each
forward-looking statement is subject to risks and uncertainties that
could cause actual results to differ materially from those expressed or
implied in such statement. Applicable risks and uncertainties include,
but are not limited to, the risk that we are unable to enroll as many
patients in the clinical study or complete the Phase IIb study on the
same timeline as we currently anticipate; the risk that the data from
the study may not be available when we currently anticipate them or do
not demonstrate the results we expect, including with respect to safety
and efficacy; the risk that the Phase IIb study needs to be discontinued
for any reason, including safety, enrollment, manufacturing or economic
reasons; the risk that the data from non-clinical or previous clinical
studies do not support the data from our clinical study; the patient
population is not as large as we presently estimate; and the risks
listed under the heading "Risk Factors" and elsewhere in Ironwood's
Annual Report on Form 10-K for the year ended December 31, 2015, in
addition to the risk factors that are listed from time to time in
Ironwood's Annual Reports on Form 10-K, Quarterly Reports on Form 10-Q
and any subsequent SEC filings. These forward-looking statements (except
as otherwise noted) speak only as of the date of this press release, and
Ironwood undertakes no obligation to update these forward-looking
statements to reflect events or circumstances occurring after this press
release. All forward-looking statements are qualified in their
entirety by this cautionary statement.
View source version on businesswire.com: http://www.businesswire.com/news/home/20160323005303/en/
Ironwood Pharmaceuticals, Inc.
Media Relations
Trista
Morrison, 617-374-5095
Director, Corporate Communications
tmorrison@ironwoodpharma.com
or
Investor
Relations
Mary T. Conway, 617-768-2628
Investor Relations
maconway@ironwoodpharma.com
Source: Ironwood Pharmaceuticals, Inc.
News Provided by Acquire Media